Tag: AV-101

November 29, 2018

VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with...
October 3, 2018

VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with...
April 10, 2018

VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today...
April 5, 2018

VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today...
January 3, 2018

VistaGen Therapeutics Gets FDA Fast Track Designation

VistaGen Therapeutics announced its candidate AV-101 received a Fast Track Designation from the FDA.
December 6, 2017

VistaGen Earns US Patent for Production Methods of AV-101

VistaGen Therapeutics announced the US Patent and Trademark Office issued a patent for "certain methods" on the production of AV-101.
October 26, 2017

VistaGen Gets FDA Approval to Begin Study of AV-101

VistaGen Therapeutics announced the US Food and Drug Administration authorized the company's investigational new drug application with a phase 2...